Improve Access to Biomarker Testing 

With the historic Food and Drug Administration (FDA) approval of treatments that slow the progression of Alzheimer’s in the early stages, early detection and diagnosis are even more critical to ensure individuals receive the most benefit at the earliest point possible. Biomarkers offer one of the most promising paths to improve dementia detection, diagnosis and treatment. Yet these critical tests remain out of reach for many as insurance coverage is failing to keep pace with innovations and advancements in treatments. The Alzheimer’s Association is urging state lawmakers to expand insurance coverage of comprehensive biomarker testing. Without this legislation, dementia diagnoses may take up to two years, increasing the long-term costs to the individual, family and the state.

Strengthen Support for Dementia Caregivers

More than 48,000 Granite State caregivers provided 77 million hours of unpaid care in 2024, often enabling their loved ones living with dementia to live in the community instead of moving into more costly residential long-term care. However, over half of the caregivers in New Hampshire are living with chronic health conditions. Respite care provides necessary relief to family caregivers, allowing the caregiver to take care of their personal medical issues, complete tasks outside the home, or simply enjoy time off from the demands of caregiving. The Alzheimer’s Association is calling on state lawmakers to increase funding levels for the state’s dementia-specific respite grant program.